NCT03882905View on ClinicalTrials.gov

A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173)

PHASE3CompletedINTERVENTIONAL
Enrollment

769

Participants

Timeline

Start Date

January 31, 2001

Primary Completion Date

July 27, 2001

Study Completion Date

July 27, 2001

Conditions
Primary Hypercholesterolemia
Interventions
DRUG

Ezetimibe

10 mg tablet, oral, once daily

DRUG

Placebo

one tablet, oral, once daily

DRUG

Simivastatin

Once daily administration at dose to be determined

DRUG

Statin

Statin administered orally once daily at dose determined by treatment prior to enrollment by personal physician

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT03882905 - A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173) | Biotech Hunter | Biotech Hunter